Two pathogen reduction technologies - Methylene blue plus light and shortwave ultraviolet light - Effectively inactivate hepatitis C virus in blood products

Transfusion

Volumn 53, Issue 5, 2013, Pages 1010-1018

  Steinmann, Eike ^b   Gravemann, Ute ^b   Friesland, Martina ^b   Doerrbecker, Juliane ^b   Müller, Thomas H ^b   Pietschmann, Thomas ^b   Seltsam, Axel ^a  

^a Institute Springe   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLENE BLUE;

ARTICLE; BLOOD; BOVINE VIRAL DIARRHEA; CELL CULTURE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; ILLUMINATION; LIMIT OF DETECTION; NONHUMAN; PHOTODYNAMIC THERAPY; ULTRAVIOLET C RADIATION; ULTRAVIOLET RADIATION; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS LOAD;

BLOOD PLATELETS; BLOOD SAFETY; CELLS, CULTURED; DIARRHEA VIRUSES, BOVINE VIRAL; HEPACIVIRUS; HUMANS; LIGHT; METHYLENE BLUE; PHOTOSENSITIZING AGENTS; PLASMA; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 84877696663     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03858.x     Document Type: Article

References (56)

1. Lavanchy D,. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
2. Hoofnagle JH,. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20S.
3. Manns MP, Wedemeyer H, Cornberg M,. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-9.
4. Jensen DM,. A new era of hepatitis C therapy begins. N Engl J Med 2011; 364: 1272-4.
5. Deterding K, Wiegand J, Gruner N, Wedemeyer H,. Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care? J Hepatol 2008; 48: 1019-20; author reply 20-1.
6. Esteban JI, Gomez J, Martell M, Cabot B, Quer J, Camps J, Gonzalez A, Otero T, Moya A, Esteban R, Guardia J,. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996; 334: 555-60.
7. Macedo de Oliveira A, White KL, Leschinsky DP, Beecham BD, Vogt TM, Moolenaar RL, Perz JF, Safranek TJ,. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med 2005; 142: 898-902.
8. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, Nass CC, Ownby HE, Schreiber GB, Kong F, Neal KR, Nemo GJ,. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31: 756-62.
9. Williams IT, Perz JF, Bell BP,. Viral hepatitis transmission in ambulatory health care settings. Clin Infect Dis 2004; 38: 1592-8.
10. Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, Reitz BA, Nelson KE,. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-73.
11. Busch MP, Tobler LH, Gerlich WH, Schaefer S, Giachetti C, Smith R,. Very low level viremia in HCV infectious unit missed by NAT. Transfusion 2003; 43: 1173-4.
12. Hakre S, Peel SA, O'Connell RJ, Sanders-Buell EE, Jagodzinski LL, Eggleston JC, Myles O, Waterman PE, McBride RH, Eader SA, Davis KW, Rentas FJ, Sateren WB, Naito NA, Tobler SK, Tovanabutra S, Petruccelli BP, McCutchan FE, Michael NL, Cersovsky SB, Scott PT,. Transfusion-transmissible viral infections among US military recipients of whole blood and platelets during Operation Enduring Freedom and Operation Iraqi Freedom. Transfusion 2011; 51: 473-85.
13. Schuttler CG, Caspari G, Jursch CA, Willems WR, Gerlich WH, Schaefer S,. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 2000; 355: 41-2.
14. Prati D,. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006; 45: 607-16.
15. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM, Blajchman MA,. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008; 22: 1-34.
16. Seghatchian J, Struff WG, Reichenberg S,. Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transfus Med Hemother 2011; 38: 55-64.
17. Mohr H, Gravemann U, Bayer A, Muller TH,. Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009; 49: 1956-63.
18. Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, Muller TH, Volker U,. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49: 2612-24.
19. Seltsam A, Müller TH,. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38: 43-54.
20. Bartenschlager R, Sparacio S,. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res 2007; 127: 195-207.
21. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM,. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.
22. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ,. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-6.
23. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV,. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 9294-9.
24. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R,. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006; 103: 7408-13.
25. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Gesamtnovelle 2005 mit Richtlinienanpassung. 2010 ed. Köln: Deutscher Ärzte-Verlag; 2010.
26. Eriksson L, Shanwell A, Gulliksson H, Hogman CF, Svensson LA, Kristensen J, Berg B,. Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies. Vox Sang 1993; 64: 133-8.
27. Gulliksson H, Larsson S, Kumlien G, Shanwell A,. Storage of platelets in additive solutions: effects of phosphate. Vox Sang 2000; 78: 176-84.
28. Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV,. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001; 11: 31-6.
29. Seghatchian J, Walker WH, Reichenberg S,. Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci 2008; 38: 271-80.
30. Anforderungen an Validierungsstudien zum Nachweis der Virussicherheit von Arzneimitteln aus menschlichem Blut oder Plasma. Verlag: Bundesanzeiger; 1994. p. 4272.
31. Kaerber G,. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1931; 162: 480-3.
32. Spearman C,. The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. Br J Psychol 1908; 2: 277-82.
33. Yanagi M, Purcell RH, Emerson SU, Bukh J,. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 1999; 262: 250-63.
34. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM,. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003; 77: 3181-90.
35. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R,. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006; 80: 5308-20.
36. CPMP/BWP/268/95. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. EMEA-CPMP 1996.
37. Kleinman SH, Lelie N, Busch MP,. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49: 2454-89.
38. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R, Giachetti C, Gallarda J, Busch MP,. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45: 994-1002.
39. Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, McCormack P, Pfahler W, Lee DH, Tobler LH, Busch M, Prince AM,. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 2003; 314: 601-16.
40. Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, Di Bisceglie AM, Shih JW, Neuwald PD,. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepat 1995; 2: 121-32.
41. Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ, Purcell RH, Yoshikura H,. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993; 67: 1953-8.
42. Busch MP, Murthy KK, Hirshkorn DF, Herring BL, Delwart EL, Racanelli V, Rehermann B, Alter HJ,. Infectivity of donations from eclipse and ramp-up stages of HCV infection in chimpanzees. Transfusion 2007; 47 Suppl: 17A.
43. Wagner SJ,. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002; 16: 61-6.
44. Bachmann B, Knuver-Hopf J, Lambrecht B, Mohr H,. Target structures for HIV-1 inactivation by methylene blue and light. J Med Virol 1995; 47: 172-8.
45. Mohr H, Lambrecht B, Selz A,. Photodynamic virus inactivation of blood components. Immunol Invest 1995; 24: 73-85.
46. Mohr H, Knuver-Hopf J, Gravemann U, Redecker-Klein A, Muller TH,. West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion 2004; 44: 886-90.
47. Cadet J, Sage E, Douki T,. Ultraviolet radiation-mediated damage to cellular DNA. Mutat Res 2005; 571: 3-17.
48. Sinha RP, Hader DP,. UV-induced DNA damage and repair: a review. Photochem Photobiol Sci 2002; 1: 225-36.
49. Lytle CD, Sagripanti JL,. Predicted inactivation of viruses of relevance to biodefense by solar radiation. J Virol 2005; 79: 14244-52.
50. Buckwold VE, Beer BE, Donis RO,. Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. Antiviral Res 2003; 60: 1-15.
51. Blumel J,. Cell culture-based assay of parvovirus B19 and the relevance of animal model viruses. Dev Biol (Basel) 2004; 118: 107-12.
52. Knuever-Hopf J, Schaefer W, Groener A, Reichenberg S, Mueller TH, Seltsam A,. Human parvovirus in plasma is highly sensitive to methylene blue/light treatment. Vox Sang 2010; 99 Suppl 1: 1-516.
53. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L,. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45: 580-90.
54. Ciesek S, Friesland M, Steinmann J, Becker B, Wedemeyer H, Manns Michael P, Steinmann J, Pietschmann T, Steinmann E,. How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. J Infect Dis 2010; 201: 1859-66.
55. Doerrbecker J, Friesland M, Ciesek S, Erichsen TJ, Mateu-Gelabert P, Steinmann J, Pietschmann T, Steinmann E,. Inactivation and survival of hepatitis C virus on inanimate surfaces. J Infect Dis 2011; 204: 1830-8.
56. Murray CL, Rice CM,. Turning hepatitis C into a real virus. Annu Rev Microbiol 2011; 65: 307-27.